Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Anderson

Showing results (61-70 of 154) with videos related to

Pageof 16
Sort By:
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 30, 2012
Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathwaysGeorge Anderson, Michael Maes, Michael Berk
Current Pharmaceutical Design|December 15, 2015
Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical ChangesTimothy V Beischlag, George Anderson, Gianluigi Mazzoccoli
International Journal of Molecular Sciences|November 8, 2019
Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune CellsGeorge Anderson, Moses Rodriguez, Russel J Reiter
CNS & Neurological Disorders Drug Targets|July 1, 2020
Inflammation and Mitochondrial Dysfunction in Autism Spectrum DisorderMaria Gevezova, Victoria Sarafian, George Anderson, et al.
Molecular Neurobiology|June 14, 2013
Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implicationsGerwyn Morris, George Anderson, Michael Berk, et al.
CNS & Neurological Disorders Drug Targets|March 25, 2015
The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic FatigueKurt Lucas, Gerwyn Morris, George Anderson, et al.
Expert Opinion on Medical Diagnostics|March 14, 2013
Diagnosis of myalgic encephalomyelitis: where are we now?Michael Maes, George Anderson, Gerwyn Morris, et al.
Expert Opinion on Therapeutic Targets|February 20, 2014
Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?Michael Maes, George Anderson, Marta Kubera, et al.
Journal of Medical Virology|January 23, 2015
Ebola virus: melatonin as a readily available treatment optionGeorge Anderson, Michael Maes, Regina P Markus, et al.
Current Pharmaceutical Design|December 15, 2015
Bipolar Disorder: The Role of the Kynurenine and Melatonergic PathwaysGeorge Anderson, Aude Jacob, Frank Bellivier, et al.
Pageof 16

Showing results (61-70 of 154) with videos related to

Sort By:
Pageof 16
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 30, 2012
Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathwaysGeorge Anderson, Michael Maes, Michael Berk
Current Pharmaceutical Design|December 15, 2015
Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical ChangesTimothy V Beischlag, George Anderson, Gianluigi Mazzoccoli
International Journal of Molecular Sciences|November 8, 2019
Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune CellsGeorge Anderson, Moses Rodriguez, Russel J Reiter
CNS & Neurological Disorders Drug Targets|July 1, 2020
Inflammation and Mitochondrial Dysfunction in Autism Spectrum DisorderMaria Gevezova, Victoria Sarafian, George Anderson, et al.
Molecular Neurobiology|June 14, 2013
Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implicationsGerwyn Morris, George Anderson, Michael Berk, et al.
CNS & Neurological Disorders Drug Targets|March 25, 2015
The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic FatigueKurt Lucas, Gerwyn Morris, George Anderson, et al.
Expert Opinion on Medical Diagnostics|March 14, 2013
Diagnosis of myalgic encephalomyelitis: where are we now?Michael Maes, George Anderson, Gerwyn Morris, et al.
Expert Opinion on Therapeutic Targets|February 20, 2014
Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?Michael Maes, George Anderson, Marta Kubera, et al.
Journal of Medical Virology|January 23, 2015
Ebola virus: melatonin as a readily available treatment optionGeorge Anderson, Michael Maes, Regina P Markus, et al.
Current Pharmaceutical Design|December 15, 2015
Bipolar Disorder: The Role of the Kynurenine and Melatonergic PathwaysGeorge Anderson, Aude Jacob, Frank Bellivier, et al.
Pageof 16